Enliven Therapeutics, Inc.
ELVN
$18.27
-$1.42-7.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -89.02M | -85.21M | -82.83M | -79.60M | -71.58M |
| Total Depreciation and Amortization | 317.00K | 315.00K | 313.00K | 309.00K | 297.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.06M | 15.00M | 10.75M | 10.29M | 8.62M |
| Change in Net Operating Assets | -4.54M | 1.43M | -403.00K | 5.22M | 1.40M |
| Cash from Operations | -73.19M | -68.47M | -72.17M | -63.79M | -61.27M |
| Capital Expenditure | -44.00K | -58.00K | -52.00K | -138.00K | -149.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.95M | 2.02M | -48.36M | -166.13M | -148.26M |
| Cash from Investing | -36.00M | 1.96M | -48.41M | -166.27M | -148.41M |
| Total Debt Issued | -- | -- | -161.37M | -162.90M | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 133.17M | 93.28M | 253.56M | 251.89M | 243.59M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -453.00K | -1.88M | -9.30M |
| Cash from Financing | 133.17M | 93.28M | 91.74M | 87.12M | 234.29M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.98M | 26.77M | -28.84M | -142.94M | 24.61M |